{"doi":"10.1016/j.msard.2025.106930","title":"Feasibility and efficacy of peak-velocity interval training vs. moderate-intensity walking training in people with multiple sclerosis with severe fatigue and walking impairment: A pilot randomized controlled trial","abstract":"INTRODUCTION: High-intensity interval training (HIIT) may yield greater improvements in walking and fatigue for people with multiple sclerosis (MS) than moderate-intensity, continuous training (MICT). This pilot project established the feasibility of peak velocity interval walking training (PVIT, a novel form of HIIT) in people with MS who had elevated fatigue and walking dysfunction and determined initial efficacy on fitness, walking, fatigue, and cognition. METHODS: Twelve people with MS [49.3 (7.4) years of age; 9 female; 1-34 years post diagnosis; Fatigue Severity Scale Score >4; Patient-Determined Disease Steps score 3-6] were randomly assigned into PVIT (n = 7) or MICT (n = 5) and completed 12 sessions of training up to 40 min. Feasibility was measured throughout as rates of recruitment, randomization, retention, adherence, and compliance. Pre- and post-assessments included peak oxygen consumption, walking performance, fatigue severity, and cognition. RESULTS: All participants who enrolled were successfully randomized and completed all sessions (100 % retention) with no adverse events. Adherence was high (86 %) as was intensity compliance (100 %) and did not differ between groups. PVIT resulted in greater walking velocity (relative to maximal overground velocity, 95 % vs. 70 %) and heart rate reserve (93 % vs. 55 %) than MICT. Peak oxygen consumption improved more in the PVIT than MICT condition (14 % vs. 1 % improvement, p < 0.05). CONCLUSION: Initial results suggest that PVIT as a form of HIIT is safe, feasible, and may improve aerobic fitness more than MICT in people with MS who have elevated fatigue and impaired walking function. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT06264336.","journal":"Multiple Sclerosis and Related Disorders","year":2025,"id":585052,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9546,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT06264336"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":441736,"name":"Brenda Jeng","orcid":"0000-0002-4522-1523","position":1,"is_corresponding":false},{"id":1498882,"name":"Natalya Brown","orcid":null,"position":2,"is_corresponding":false},{"id":385581,"name":"Robert W. Motl","orcid":"0000-0002-5894-2290","position":3,"is_corresponding":false},{"id":383692,"name":"Sangeetha Madhavan","orcid":"0000-0001-6086-0027","position":4,"is_corresponding":false},{"id":388102,"name":"Brice T. Cleland","orcid":"0000-0001-8227-6876","position":0,"is_corresponding":true}],"reference_count":54,"raw_metadata":null,"created_at":"2026-07-19T02:59:20.067334Z","pmid":"41418486","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}